Innovative Drug Discovery ExcepGen specializes in leveraging engineered human cell lines to produce full-length human proteins, addressing key bottlenecks in drug discovery which presents opportunities for partnering with biopharma companies seeking advanced research tools.

Strong Funding and Backing With recent $4 million seed funding and investments from notable venture capitalists such as ZAKA VC, RA Capital Management, Gravity Fund, and Apollo Projects, ExcepGen is positioned for growth and strategic collaborations.

Strategic Industry Collaborations Having launched with partnerships involving three major pharmaceutical companies and aiming to develop its own pipeline, ExcepGen offers avenues for pharmaceutical firms to integrate innovative biologics technologies into their development pipelines.

Emerging Market Potential As an early-stage biotech with a focus on biologics and drug discovery, ExcepGen is well-placed to serve biotech and pharma clients seeking cutting-edge solutions to accelerate their research and reduce time-to-market.

Technology and Platform Focus Utilizing a tech stack that includes cloud services and web technologies, ExcepGen is enhancing its research capabilities and data management, providing opportunities to supply technology solutions or data analytics platforms tailored for biotech research.